Olivier Chaudoir Joins BioSig as Director of Marketing
July 18 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
device company developing a proprietary biomedical signal
processing technology platform designed to address an unmet need
for the electrophysiology (EP) marketplace, today announced that
Mr. Olivier Chaudoir joined the Company as Director of Marketing.
Mr. Chaudoir brings to BioSig over 20 years of medical
technology experience, including over 15 years in
electrophysiology. Most recently, Mr. Chaudoir served as WW Senior
Global Strategic Marketing Director at DePuy Synthes (a Johnson
& Johnson company), a role, during which he led strategic
competitive assessments in the sector of spinal enabling
technologies and established a multi-generation technology roadmap
and execution plan. Prior to it, Mr. Chaudoir spent 17 years at
Biosense Webster in the U.S., France and Belgium. During this time,
he progressed from the field clinical support roles to Atrial
Fibrillation Specialist to Regional Business Director and
successfully led the company’s operations in Northern and Southern
California. One of the highlights of Mr. Chaudoir’s career include
a successful global launch of CARTOÒ3 Navigation System. Mr.
Chaudoir’s contributions to this product launch include development
of innovative commercial marketing programs to enable customer
acceptance for the US, Japanese and Chinese electrophysiology
markets. Mr. Chaudoir is a holder of a Marketing Mastery Award
(FUSE JNJ MD&D Global Surgery). He graduated from Pole
Academique de Bruxelles (Belgium) school with the BSc degree in
Biomedical Electronics Engineering and University of Sussex in the
UK with a MSc degree in Digital Electronics and Parallel Processing
Systems. Mr. Chaudoir completed The Berkeley Executive Leadership
Program and is bilingual in French and English.
“We are very happy that Olivier joined us during this exciting
time in our Company’s evolution. A marketing function is a critical
component of a successful market launch, and we were very impressed
with Olivier’s accomplishments in electrophysiology sector, as well
as his personal drive and determination to go that extra mile for
the Company’s success,” stated Kenneth L. Londoner, Founder,
Chairman and CEO of BioSig Technologies, Inc. “We look forward to
learning from Olivier as we prepare for the targeted market release
later this year.”
BioSig recently announced that it has been added to the Russell
3000 Index and was allowed 33 patent claims covering its PURE EP™
System. In the first half of 2019 BioSig successfully conducted
first patient cases using its PURE EP™ System at the Texas Cardiac
Arrhythmia Institute in Austin, TX, Greenville Memorial Hospital in
Greenville, SC and Indiana University School of Medicine. These
initial experiences suggested improved cardiac signal detection and
fidelity.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EP™ System. The
technology has been developed to address an unmet need in a large
and growing market.The Company’s first product, PURE EP™ System is
a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory. The system is indicated for use under the
supervision of licensed healthcare practitioners who are
responsible for interpreting the data. This novel cardiac signal
acquisition and display system is engineered to assist
electrophysiologists in clinical decision-making during
electrophysiology procedures in patients with abnormal heart rates
and rhythms. BioSig’s ultimate goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and
potentially deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
310-620-9320
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024